Business & Industry

The US Food and Drug Administration (FDA) has granted accelerated approval to Sanofi’s Tzield (teplizumab-mzwv) for children aged eight to 17 years who have recently been diagnosed with stage 3 type 1 diabetes (T1D). The decision allows the therapy...

Celltrion has strengthened its footprint in Vietnam by introducing two oncology biosimilars, further expanding its portfolio in one of Southeast Asia’s rapidly growing pharmaceutical markets. The company announced that commercial sales of Truxima (rituximab), used in the treatment of...

Australia’s Sigma Healthcare has confirmed that it is participating in discussions regarding a possible acquisition of Boots, the UK health and beauty retailer, in a transaction reportedly valued at up to $10 billion. The company acknowledged its interest after...

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced the launch of a new AI Sandbox programme designed to explore how artificial intelligence can strengthen medicines safety, improve risk prediction and support faster development of new treatments. Announced...

Pfizer has secured an expanded indication approval from the US Food and Drug Administration (FDA) for Hympavzi (marstacimab-hncq), broadening its use in the treatment of haemophilia A or B. The updated approval extends coverage to patients aged 12 years...

Incyte has agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, in a transaction valued at up to $2bn, reinforcing its presence in haematology with the addition of a late-stage treatment candidate for bleeding disorders. Under the terms...

GSK has agreed to acquire Nuvalent in a transaction valued at $10.6 billion, positioning the UK-based pharmaceutical company for its largest acquisition in more than a decade and adding two late-stage lung cancer treatments to its portfolio. Through a...